Evolocumab: lowering of both the LDL cholesterol and cardiovascular risk

Abstract

Evolocumab is a fully human monoclonal antibody against PCSK9. Its lipid lowering effect is significant and reaches 50-70% additional LDL-c lowering when added to standard therapies.

Evolocumab is being tested in a large research programme PROFICIO.

Keywords

• Cardiovascular risk
• LDL‑cholesterol
• evolocumab
• monoclonal antibodies